Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

815 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC Jr. Fu S, et al. Among authors: markman m. Cancer. 2011 Apr 15;117(8):1661-9. doi: 10.1002/cncr.25701. Epub 2010 Nov 8. Cancer. 2011. PMID: 21472713 Free PMC article. Clinical Trial.
Ovarian cancer.
Hennessy BT, Coleman RL, Markman M. Hennessy BT, et al. Among authors: markman m. Lancet. 2009 Oct 17;374(9698):1371-82. doi: 10.1016/S0140-6736(09)61338-6. Epub 2009 Sep 28. Lancet. 2009. PMID: 19793610
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC Jr, Mills GB. Fu S, et al. Among authors: markman m. Gynecol Oncol. 2012 Jul;126(1):47-53. doi: 10.1016/j.ygyno.2012.04.006. Epub 2012 Apr 6. Gynecol Oncol. 2012. PMID: 22487539 Free PMC article. Clinical Trial.
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
Coleman RL, Moon J, Sood AK, Hu W, Delmore JE, Bonebrake AJ, Anderson GL, Chambers SK, Markman M. Coleman RL, et al. Among authors: markman m. Eur J Cancer. 2014 Jun;50(9):1638-48. doi: 10.1016/j.ejca.2014.03.005. Epub 2014 Apr 4. Eur J Cancer. 2014. PMID: 24709487 Free PMC article. Clinical Trial.
Epithelial ovarian cancer: focus on targeted therapy.
Markman M, Sehouli J, Levenback CF, Chi DS. Markman M, et al. J Oncol. 2010;2010:171425. doi: 10.1155/2010/171425. Epub 2011 Jul 5. J Oncol. 2010. PMID: 21804823 Free PMC article. No abstract available.
Emerging therapeutics for primary peritoneal cancer.
Slomovitz BM, Worley MJ, Markman M, Coleman RL. Slomovitz BM, et al. Among authors: markman m. Expert Opin Emerg Drugs. 2011 Mar;16(1):71-84. doi: 10.1517/14728214.2011.526600. Expert Opin Emerg Drugs. 2011. PMID: 21352070 Review.
815 results